Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.Polycythemia Vera: A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.Primary Myelofibrosis: A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.Janus Kinase 2: A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.Thrombocythemia, Essential: A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.Thrombocytosis: Increased numbers of platelets in the peripheral blood. (Dorland, 27th ed)Receptors, Thrombopoietin: Cell surface receptors that are specific for THROMBOPOIETIN. They signal through interaction with JANUS KINASES such as JANUS KINASE 2.Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative: A myelodysplastic/myeloproliferative disorder characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to CHRONIC MYELOID LEUKEMIA, but cytogenetically lacking a PHILADELPHIA CHROMOSOME or bcr/abl fusion gene (GENES, ABL).Leukemia, Myelomonocytic, Chronic: A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.Splenomegaly: Enlargement of the spleen.Hematopoiesis, Extramedullary: The formation and development of blood cells outside the BONE MARROW, as in the SPLEEN; LIVER; or LYMPH NODES.Leukemia, Neutrophilic, Chronic: A rare myeloproliferative disorder that is characterized by a sustained, mature neutrophilic leukocytosis. No monocytosis, EOSINOPHILIA, or basophilia is present, nor is there a PHILADELPHIA CHROMOSOME or bcr-abl fusion gene (GENES, ABL).Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.Leukemia, Myelomonocytic, Juvenile: A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.Hematopoietic Stem Cells: Progenitor cells from which all blood cells derive.Leukemia, Megakaryoblastic, Acute: An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.Granulocytes: Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)Fusion Proteins, bcr-abl: Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.Megakaryocytes: Very large BONE MARROW CELLS which release mature BLOOD PLATELETS.Receptor, Fibroblast Growth Factor, Type 1: A fibroblast growth factor receptor with specificity for FIBROBLAST GROWTH FACTORS; HEPARAN SULFATE PROTEOGLYCAN; and NEURONAL CELL ADHESION MOLECULES. Several variants of the receptor exist due to multiple ALTERNATIVE SPLICING of its mRNA. Fibroblast growth factor receptor 1 is a tyrosine kinase that transmits signals through the MAP KINASE SIGNALING SYSTEM.Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Polycythemia: An increase in the total red cell mass of the blood. (Dorland, 27th ed)Myelodysplastic-Myeloproliferative Diseases: Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.Hepatomegaly: Enlargement of the liver.Translocation, Genetic: A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.Hypereosinophilic Syndrome: A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.Leukocytosis: A transient increase in the number of leukocytes in a body fluid.Chromosomes, Human, Pair 8: A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.Budd-Chiari Syndrome: A condition in which the hepatic venous outflow is obstructed anywhere from the small HEPATIC VEINS to the junction of the INFERIOR VENA CAVA and the RIGHT ATRIUM. Usually the blockage is extrahepatic and caused by blood clots (THROMBUS) or fibrous webs. Parenchymal FIBROSIS is uncommon.Genes, abl: Retrovirus-associated DNA sequences (abl) originally isolated from the Abelson murine leukemia virus (Ab-MuLV). The proto-oncogene abl (c-abl) codes for a protein that is a member of the tyrosine kinase family. The human c-abl gene is located at 9q34.1 on the long arm of chromosome 9. It is activated by translocation to bcr on chromosome 22 in chronic myelogenous leukemia.Thrombopoietin: A humoral factor that stimulates the production of thrombocytes (BLOOD PLATELETS). Thrombopoietin stimulates the proliferation of bone marrow MEGAKARYOCYTES and their release of blood platelets. The process is called THROMBOPOIESIS.Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.Hematopoiesis: The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).Mutation, Missense: A mutation in which a codon is mutated to one directing the incorporation of a different amino acid. This substitution may result in an inactive or unstable product. (From A Dictionary of Genetics, King & Stansfield, 5th ed)Oncogene Proteins, Fusion: The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin.Hydroxyurea: An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.Chromosomes, Human, Pair 20: A specific pair of GROUP F CHROMOSOMES of the human chromosome classification.Blast Crisis: An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.X Chromosome Inactivation: A dosage compensation process occurring at an early embryonic stage in mammalian development whereby, at random, one X CHROMOSOME of the pair is repressed in the somatic cells of females.Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.Myelopoiesis: Formation of MYELOID CELLS from the pluripotent HEMATOPOIETIC STEM CELLS in the BONE MARROW via MYELOID STEM CELLS. Myelopoiesis generally refers to the production of leukocytes in blood, such as MONOCYTES and GRANULOCYTES. This process also produces precursor cells for MACROPHAGE and DENDRITIC CELLS found in the lymphoid tissue.Colony-Forming Units Assay: A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.Chromosomes, Human, Pair 5: One of the two pairs of human chromosomes in the group B class (CHROMOSOMES, HUMAN, 4-5).Benzamides: BENZOIC ACID amides.Anemia, Refractory, with Excess of Blasts: Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.Bone Marrow Cells: Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.Platelet Count: The number of PLATELETS per unit volume in a sample of venous BLOOD.Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)Bone Marrow Neoplasms: Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.GATA1 Transcription Factor: A GATA transcription factor that is specifically expressed in hematopoietic lineages and plays an important role in the CELL DIFFERENTIATION of ERYTHROID CELLS and MEGAKARYOCYTES.Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.Philadelphia Chromosome: An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).Hydrops Fetalis: Abnormal accumulation of serous fluid in two or more fetal compartments, such as SKIN; PLEURA; PERICARDIUM; PLACENTA; PERITONEUM; AMNIOTIC FLUID. General fetal EDEMA may be of non-immunologic origin, or of immunologic origin as in the case of ERYTHROBLASTOSIS FETALIS.Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)Blood Cell Count: The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.Pyrimidines: A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.PiperazinesHematologic Diseases: Disorders of the blood and blood forming tissues.Janus Kinases: A family of intracellular tyrosine kinases that participate in the signaling cascade of cytokines by associating with specific CYTOKINE RECEPTORS. They act upon STAT TRANSCRIPTION FACTORS in signaling pathway referred to as the JAK/STAT pathway. The name Janus kinase refers to the fact the proteins have two phosphate-transferring domains.Chromosomes, Human, X: The human female sex chromosome, being the differential sex chromosome carried by half the male gametes and all female gametes in humans.Anxiety Disorders: Persistent and disabling ANXIETY.DNA Mutational Analysis: Biochemical identification of mutational changes in a nucleotide sequence.Myeloid Progenitor Cells: Stem cells derived from HEMATOPOIETIC STEM CELLS. Derived from these myeloid progenitor cells are the MEGAKARYOCYTES; ERYTHROID CELLS; MYELOID CELLS; and some DENDRITIC CELLS.Mood Disorders: Those disorders that have a disturbance in mood as their predominant feature.Myeloid Cells: The classes of BONE MARROW-derived blood cells in the monocytic series (MONOCYTES and their precursors) and granulocytic series (GRANULOCYTES and their precursors).Point Mutation: A mutation caused by the substitution of one nucleotide for another. This results in the DNA molecule having a change in a single base pair.Chromosomes, Human, Pair 13: A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.Karyotyping: Mapping of the KARYOTYPE of a cell.Protein-Tyrosine Kinases: Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.Gene Expression Regulation, Leukemic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.Proto-Oncogene Proteins: Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.Erythroid Precursor Cells: The cells in the erythroid series derived from MYELOID PROGENITOR CELLS or from the bi-potential MEGAKARYOCYTE-ERYTHROID PROGENITOR CELLS which eventually give rise to mature RED BLOOD CELLS. The erythroid progenitor cells develop in two phases: erythroid burst-forming units (BFU-E) followed by erythroid colony-forming units (CFU-E); BFU-E differentiate into CFU-E on stimulation by ERYTHROPOIETIN, and then further differentiate into ERYTHROBLASTS when stimulated by other factors.Amino Acid Substitution: The naturally occurring or experimentally induced replacement of one or more AMINO ACIDS in a protein with another. If a functionally equivalent amino acid is substituted, the protein may retain wild-type activity. Substitution may also diminish, enhance, or eliminate protein function. Experimentally induced substitution is often used to study enzyme activities and binding site properties.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Receptor, Platelet-Derived Growth Factor beta: A PDGF receptor that binds specifically to the PDGF-B chain. It contains a protein-tyrosine kinase activity that is involved in SIGNAL TRANSDUCTION.Bone Marrow Transplantation: The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.Receptors, Fibroblast Growth Factor: Specific molecular sites or structures on cell membranes that react with FIBROBLAST GROWTH FACTORS (both the basic and acidic forms), their analogs, or their antagonists to elicit or to inhibit the specific response of the cell to these factors. These receptors frequently possess tyrosine kinase activity.Splenectomy: Surgical procedure involving either partial or entire removal of the spleen.Neurofibromin 1: A protein found most abundantly in the nervous system. Defects or deficiencies in this protein are associated with NEUROFIBROMATOSIS 1, Watson syndrome, and LEOPARD syndrome. Mutations in the gene (GENE, NEUROFIBROMATOSIS 1) affect two known functions: regulation of ras-GTPase and tumor suppression.Chromosomes, Human, Pair 9: A specific pair of GROUP C CHROMSOMES of the human chromosome classification.Clone Cells: A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)Core Binding Factor Alpha 2 Subunit: A transcription factor that dimerizes with the cofactor CORE BINDING FACTOR BETA SUBUNIT to form core binding factor. It contains a highly conserved DNA-binding domain known as the runt domain. Runx1 is frequently mutated in human LEUKEMIAS.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Diagnostic and Statistical Manual of Mental Disorders: Categorical classification of MENTAL DISORDERS based on criteria sets with defining features. It is produced by the American Psychiatric Association. (DSM-IV, page xxii)In Situ Hybridization, Fluorescence: A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.Phenotype: The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.Polymerase Chain Reaction: In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Blood Platelets: Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.Sarcoma Viruses, Murine: A group of replication-defective viruses, in the genus GAMMARETROVIRUS, which are capable of transforming cells, but which replicate and produce tumors only in the presence of Murine leukemia viruses (LEUKEMIA VIRUS, MURINE).Chromosome Aberrations: Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.Receptors, Cytokine: Cell surface proteins that bind cytokines and trigger intracellular changes influencing the behavior of cells.Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.Antigens, CD34: Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Eosinophilia: Abnormal increase of EOSINOPHILS in the blood, tissues or organs.Spleen: An encapsulated lymphatic organ through which venous blood filters.Leukocyte Count: The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.Retroviridae: Family of RNA viruses that infects birds and mammals and encodes the enzyme reverse transcriptase. The family contains seven genera: DELTARETROVIRUS; LENTIVIRUS; RETROVIRUSES TYPE B, MAMMALIAN; ALPHARETROVIRUS; GAMMARETROVIRUS; RETROVIRUSES TYPE D; and SPUMAVIRUS. A key feature of retrovirus biology is the synthesis of a DNA copy of the genome which is integrated into cellular DNA. After integration it is sometimes not expressed but maintained in a latent state (PROVIRUSES).Receptors, Erythropoietin: Cell surface proteins that bind erythropoietin with high affinity and trigger intracellular changes influencing the behavior of cells.Chromosome Disorders: Clinical conditions caused by an abnormal chromosome constitution in which there is extra or missing chromosome material (either a whole chromosome or a chromosome segment). (from Thompson et al., Genetics in Medicine, 5th ed, p429)Blood Cells: The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.Genetic Testing: Detection of a MUTATION; GENOTYPE; KARYOTYPE; or specific ALLELES associated with genetic traits, heritable diseases, or predisposition to a disease, or that may lead to the disease in descendants. It includes prenatal genetic testing.Moloney murine sarcoma virus: A replication-defective murine sarcoma virus (SARCOMA VIRUSES, MURINE) isolated from a rhabdomyosarcoma by Moloney in 1966.Mice, Inbred C57BLMice, Transgenic: Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.Receptor Protein-Tyrosine Kinases: A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity.Erythropoiesis: The production of red blood cells (ERYTHROCYTES). In humans, erythrocytes are produced by the YOLK SAC in the first trimester; by the liver in the second trimester; by the BONE MARROW in the third trimester and after birth. In normal individuals, the erythrocyte count in the peripheral blood remains relatively constant implying a balance between the rate of erythrocyte production and rate of destruction.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Anemia, Refractory: A severe sometimes chronic anemia, usually macrocytic in type, that does not respond to ordinary antianemic therapy.Protein Kinase Inhibitors: Agents that inhibit PROTEIN KINASES.STAT5 Transcription Factor: A signal transducer and activator of transcription that mediates cellular responses to a variety of CYTOKINES. Stat5 activation is associated with transcription of CELL CYCLE regulators such as CYCLIN KINASE INHIBITOR P21 and anti-apoptotic genes such as BCL-2 GENES. Stat5 is constitutively activated in many patients with acute MYELOID LEUKEMIA.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Depressive Disorder, Major: Marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation.
Atypical chronic myeloid leukemia
La Jolla Institute for Allergy and Immunology
Chronic Neutrophilic Leukemia | Annals of Internal Medicine | American College of Physicians
Myeloproliferative Disorders Group - Overview - Mayo Clinic
Myeloproliferative Disorders Support Group - Drugs.com
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic...
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or...
EMF-Portal | Residential exposure to electric power transmission lines and risk of lymphoproliferative and myeloproliferative...
Atopic dermatitis-like disease and associated lethal myeloproliferative disorder arise from loss of Notch signaling in the...
SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic...
TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative...
Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®): Treatment - Health Professional Information [NCI] | Cigna
Atypical chronic myeloid leukemia - Wikipedia
Diagnosis And Classification Of Myeloproliferative And... | Bartleby
Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and...
Dr Mark Drummond | Edinburgh Hospitals, Murrayfield and Shawfair Park | Spire Healthcare
Respiratory Medicine Flashcards by Shaun Trussell | Brainscape
Lisa Mills, MD | Summit Medical Group
Winnie Polen, DO | Summit Medical Group
Management of Pulmonary Hypertension - Renal and Urology News
ClonalMyelofibrosisDiseasesMyeloid disordersThrombocytosisDiagnosisHemopoiesisNeoplasmsMPNsMyelofibrosisMyelodysplastic SyndromePolycythemia veraThrombocytosisJAK2Chronic myeloproliferative diseasesKnown as myeloproliferativeMPDsDiseases called myeloproliferative disordersLeukemias and myeloproliferative disordersAcute leukemiasHematologic2016LeukemiaLymphoproliferative disordersHematologyDiagnosisSplenomegalyPatients with myeloproliferativeHeterogeneousHematopoietic stemOverlapOverproductionPlatelet countPrimaryProliferationThrombocythemiaEssentialBloodLymphomasBone MarrowCoagulation DisordersClonal stem cellMolecularJakafiPlateletsPulmonary HypertensionTreatment
Clonal1
- As one of the myeloproliferative syndromes, essential thrombocythemia is a clonal disorder of the multipotential hemopoietic stem cell. (wordpress.com)
Myelofibrosis2
- Essential (primary) thrombocythemia is one of a group of related chronic myeloproliferative disorders that also includes polycythemia vera, chronic myelogenous leukemia, and myeloid metaplasia with or without myelofibrosis. (wordpress.com)
- Primary Myelofibrosis (PMF) is a chronic myeloproliferative disorder characterized by bone marrow fibrosis , splenomegaly , and anemia with nucleated and teardrop-shaped RBCs. (askhematologist.com)
Diseases1
- The routine clinical chemistry laboratory classically provides only limited help in distinguishing between reactive thrombocytosis (RT) and autonomous thrombocytosis, where platelet production escapes normal regulatory processes, and which is seen in myeloproliferative diseases (MPD) such as essential thrombocythemia and polycythemia vera. (uclouvain.be)
Myeloid disorders1
- Cytogenetic studies of bone marrow are helpful in excluding chronic myelogenous leukemia (CML), myelodysplastic syndrome, or other chronic myeloid disorders. (askhematologist.com)
Thrombocytosis1
- The earliest descriptions of essential thrombocythemia by di Guglielmo in 1920 and by Epstein and Goedel in 19342 represented, in retrospect, thrombocytosis in association with other disorders. (wordpress.com)
Diagnosis1
- some patients have a rapidly progressing disorder with short survival and some have a delay in initial diagnosis. (askhematologist.com)
Hemopoiesis1
- In this disorder, marrow fibrosis and extramedullary hemopoiesis (primarily in the liver and spleen) predominate. (askhematologist.com)
Neoplasms34
- The myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either myelodysplastic syndromes (MDS) or chronic myeloproliferative disorders (CMPD). (cigna.com)
- An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. (cigna.com)
- HEMATOLOGIC CHARACTERISTICS OF MYELOPROLIFERATIVE NEOPLASMS Myeloproliferative neoplasms (MPNs) are characterized by the proliferation of one or more cell types of the myeloid lineage, including erythroid, granulocytic, monocytic, or megakaryocytic lineages. (bartleby.com)
- The myeloproliferative neoplasms ( MPNs ), previously myeloproliferative diseases ( MPDs ), are a group of diseases of the bone marrow in which excess cells are produced. (wikipedia.org)
- We previously found that gender influenced the JAK2 V617F allele burden, but it is unknown whether this gender difference in molecular epidemiology influences complications in the myeloproliferative neoplasms (MPNs). (hindawi.com)
- The myeloproliferative neoplasms (MPNs), essential thrombocytosis (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) share the same acquired genetic lesion, JAK2 V617F, which may explain shared tendencies towards cardinal complications, which include thrombosis, extramedullary hematopoiesis, evolution between phenotypes, and leukemic transformation. (hindawi.com)
- The myeloproliferative neoplasms (MPNs), previously termed the myeloproliferative disorders , are characterized by the clonal proliferation of one or more hematopoietic cell lineages, predominantly in the bone marrow, but sometimes in the liver and spleen. (clevelandclinicmeded.com)
- The evolving genomic landscape of myeloproliferative neoplasms. (clevelandclinicmeded.com)
- Essential thrombocythemia belongs to a group of diseases called myeloproliferative neoplasms , which cause the bone marrow to make too many platelets , white blood cells and/or red blood cells . (nih.gov)
- However, it is important to distinguish PV from essential thrombocythemia (ET) given that PV is one of the commonest myeloproliferative neoplasms and can often resemble ET. (haematologica.org)
- Myeloproliferative neoplasms (MPNs) are still difficult to treat. (innovations-report.com)
- Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). (jnccn.org)
- Earlier this year we met our goal of enrolling 1,000 people in a community of people with a collection of rare blood disorders known as myeloproliferative neoplasms, or MPNs. (23andme.com)
- 23andMe is applying its unique research platform to study cancer with research communities focused on sarcoma, myeloproliferative neoplasms, and metastatic breast cancer. (23andme.com)
- Myeloproliferative neoplasms (MPN) are a group of rare blood disorders. (23andme.com)
- Myeloproliferative neoplasms (MPNs) are a subset of bone marrow disorders . (labtestsonline.org.au)
- with special interest in acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms and bone marrow transplants. (petermac.org)
- Myeloproliferative neoplasms are a group of disorders characterised by clonal growth in one or more haematopoietic cell lines. (tidsskriftet.no)
- Essential thrombocythemia belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). (cancerconnect.com)
- The MPN Research Foundation has a single goal: to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera,essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPNs). (mpnresearchfoundation.org)
- To make a difference in the lives of those affected by myeloproliferative neoplasms. (lls.org)
- to increase awareness amongst patients, physicians and caregivers of myeloproliferative neoplasms. (lls.org)
- To provide a comprehensive, easy to navigate resource hub for the study of Myeloproliferative Neoplasms (MPNs) such as Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis. (lls.org)
- Patients with chronic leukemia, myeloproliferative disorders, MDS, or acute leukemia were excluded from cases of primary neoplasms. (aacrjournals.org)
- Primary myelofibrosis belongs to a group of diseases known as the myeloproliferative neoplasms (MPNs). (rarediseases.org)
- We treat a number of blood and bone marrow disorders, including aplastic anemia, myeloproliferative neoplasms and myelodysplastic syndromes. (northwestern.edu)
- Chronic myeloproliferative neoplasms are diseases in which the bone marrow makes too many red blood cells, platelets or certain white blood cells. (northwestern.edu)
- Certain types of myeloproliferative neoplasms and myelodysplastic syndromes may become a type of blood cancer called acute leukemia. (northwestern.edu)
- See also Overview of Myeloproliferative Neoplasms . (merckmanuals.com)
- The main myeloproliferative neoplasms are essential thrombocythemia (ET), polycythemia vera, and primary myelofibrosis. (eas-society.org)
- Myeloproliferative neoplasms (MPNs) are a group of clonal disorders characterized by hyperproliferation of hematologic cell lines and have been associated with tyrosine kinase JAK2-V617F mutations. (jove.com)
- When the late Murray Silverstein (1928-1998), a Mayo Clinic physician-scientist par excellence, 1 introduced me to the subspecialty practice of myeloproliferative neoplasms (MPNs) in the early 1990s, hydroxyurea had already been established as the antithrombotic treatment of choice for polycythemia vera (PV). (bloodjournal.org)
- Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). (unm.edu)
- Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). (aamds.org)
MPNs2
- MPNs are a group of rare, malignant diseases of the bone marrow involving the production of an excess of red blood cells, white blood cells and/or platelets. (innovations-report.com)
- Three other disorders are commonly classified as MPNs: chronic myeloid leukemia, essential thrombocythemia and polycythemia vera. (rarediseases.org)
Myelofibrosis14
- Myelofibrosis is a serious bone marrow disorder that disrupts your body's normal production of blood cells. (mayoclinic.org)
- Myelofibrosis belongs to a group of diseases called myeloproliferative disorders. (mayoclinic.org)
- Myelofibrosis is a disorder of the spongy tissue inside the bone (bone marrow) that contains the stem cells that will form blood cells . (nih.gov)
- JAK2 mutations have been recently described in chronic myeloproliferative disorders (95% of polycythaemia vera, 50-60% of essential thrombocythemia, 50-60% of primary myelofibrosis). (imim.es)
- Chronic idiopathic myelofibrosis is a myeloproliferative disorder characterized by splenomegaly, myeloid metaplasia and reactive bone marrow fibrosis. (thefreelibrary.com)
- Calreticulin ( CALR ) and myeloproliferative leukemia virus oncogene ( MPL ) mutations are specific to JAK2 -unmutated essential thrombocythemia (ET) and primary myelofibrosis (PMF). (bloodjournal.org)
- Idiopathic Myelofibrosis is a rare myeloproliferative disorder. (thefreedictionary.com)
- It is a subset of myeloproliferative disorder (eg, essential thrombocythemia [ET]), myelofibrosis with myeloid metaplasia, polycythemia vera , chronic myelocytic leukemia (CML) or, in rare cases, acute myelocytic leukemia. (medscape.com)
- This group of diseases includes myelofibrosis, polycythemia vera and essential thrombocythemia. (bio-medicine.org)
- Myeloproliferative disorders are a group of diseases including myelofibrosis, polycythemia vera (PV) and essential thrombocythemia (ET) that affect over 150,000 patients in the USA and more than twice that worldwide. (mpnresearchfoundation.org)
- Myelofibrosis with myeloid metaplasia , also known as agnogenic myeloid metaplasia , chronic idiopathic myelofibrosis , and primary myelofibrosis , was first described in 1879 and is currently classified as a myeloproliferative disease caused by the growth and proliferation of an abnormal bone marrow stem cell, resulting in the replacement of the bone marrow with fibrous connective tissue . (bionity.com)
- Primary myelofibrosis (PMF) is a rare bone marrow disorder that is characterized by abnormalities in blood cell production (hematopoiesis) and scarring (formation of fibrous tissue) within the bone marrow. (rarediseases.org)
- He is past editor of the British Journal of Haematology and a founder member of the International Working Group for Myelofibrosis treatment and Research (IWG-MRT) and the UK Chronic Myeloproliferative Disorders Group. (sheffield.ac.uk)
- Therefore, risk-benefit balance favors use of currently available JAK inhibitors in only a select group of patients with myelofibrosis, and their potential value in polycythemia vera, outside of special circumstances (eg, intractable pruritus), is undermined by the absence of evidence for a disease-modifying effect and presence of arguably superior alternatives. (bloodjournal.org)
Myelodysplastic Syndrome5
- The diseases and disorders of the bone marrow include Leukemia, Myelodysplastic Syndrome, Myeloproliferative disorders and so forth. (news-medical.net)
- They are related to, and may evolve into, myelodysplastic syndrome and acute myeloid leukemia , although the myeloproliferative diseases on the whole have a much better prognosis than these conditions. (wikipedia.org)
- Clonal or primary eosinophilia is generally associated with chronic myeloproliferative disorders (Eos-MPD), including atypical chronic myeloid leukemia (aCML), myeloproliferative variant of HES (M-HES), chronic myelomonocytic leukemia (CMML), unclassifiable overlap syndromes of myelodysplastic syndrome/myeloproliferative disorders (MDS/MPD) and systemic mastocytosis (SM). (haematologica.org)
- Currently, the World Health Organization (WHO) classifies JMML as an overlap myelodysplastic syndrome/myeloproliferative disorder because JMML shares characteristics with both of these groups of disorders. (rarediseases.org)
- We diagnosed this case of thrombocytosis and anemia as myelodysplastic syndrome and/or myeloproliferative disorder-unclassifiable (MDS/MPD-U), and the aortic thrombus was thought to be associated with myeloproliferative thrombocytosis. (biomedcentral.com)
Polycythemia vera8
- Polycythemia vera is a chronic myeloproliferative disorder characterized by increased red blood cell mass. (aafp.org)
- Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by an increased red blood cell mass (RCM), or erythrocytosis, which leads to hyperviscosity and an increased risk of thrombosis. (aafp.org)
- 5 , 6 Once a secondary cause is ruled out ( Table 2 7 ), the diagnosis of PV is made using a combination of major and minor criteria defined by the Polycythemia Vera Study Group (PVSG). (aafp.org)
- Polycythemia vera is a clonal disorder characterized by the overproduction of mature red blood cells. (clevelandclinicmeded.com)
- The demonstration of an increased red cell mass (RCM) measured by isotopic methods was the main criterion for the diagnosis of polycythemia vera (PV) according to the Polycythemia Vera Study Group. (haematologica.org)
- Polycythemia vera (PV) is a chronic myeloproliferative disorder associated with cardiovascular events. (medsci.org)
- We report a case that was recognized during investigation of a transient ischemic attack, and review the neurologic findings in 33 patients with unequivocal essential thrombocythemia under prospective study by the Polycythemia Vera Study Group. (annals.org)
- In addition to AMM, the group includes essential thrombocythemia (ET), and polycythemia vera (PV), both of which may undergo delayed disease transformation into a fibrotic state called postthrombocythemic myeloid metaplasia (PTM) and postpolycythemic myeloid metaplasia (PPM), respectively. (bionity.com)
Thrombocytosis11
- In addition, primary thrombocytosis due to myeloproliferative disorder is commonly associated with anemia and leukocytosis. (medscape.com)
- It is usually reactive following other myeloproliferative disorders , such as polycythemia rubra vera or essential thrombocytosis . (bionity.com)
- Thrombosis in myeloproliferative thrombocytosis occurs usually in the microvessels and medium-sized arteries and veins and only rarely in the aorta. (biomedcentral.com)
- Thrombocytosis is classified into myeloproliferative thrombocytosis and reactive thrombocytosis. (biomedcentral.com)
- In myeloproliferative thrombocytosis, there is always a risk of thrombosis. (biomedcentral.com)
- It is well known that thrombosis in myeloproliferative thrombocytosis occurs in the medium-sized arteries and veins and in the microvessels [ 1 ]. (biomedcentral.com)
- We report a rare case of aortic thrombosis with myeloproliferative thrombocytosis. (biomedcentral.com)
- For myeloproliferative thrombocytosis, she was treated with 500 mg of hydroxyurea from the seventh day of her hospital stay. (biomedcentral.com)
- Ticlopidine was administered to prevent the development of a thrombosis on the seventh hospital day, which was the same day treatment for myeloproliferative thrombocytosis was initiated. (biomedcentral.com)
- One symptom shared by all myeloproliferative disorders, with the exception of essential thrombocytosis, is an enlarged spleen. (adam.com)
- A sign shared by all myeloproliferative disorders, with the exception of essential thrombocytosis, is an enlarged spleen. (adam.com)
JAK27
- The disorder occurs when blood stem cells develop somatic mutations in the JAK2 , MPL , CALR , and TET2 genes . (nih.gov)
- CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders. (bio-medicine.org)
- Hyperactivity of the JAK2 enzyme is known to cause a number of haematological conditions known as myeloproliferative disorders (MPDs). (bio-medicine.org)
- Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK1/JAK2 inhibitor focused on the treatment of myeloproliferative disorders, to enter Phase I clinical studies in 2009. (bio-medicine.org)
- 03/18/2008 Cytopia Limited (ASX:CYT) has selected CYT387, a selective and potent JAK2 inhibitor, for formal preclinical development to treat myeloproliferative disorders (MPDs). (mpnresearchfoundation.org)
- studied how patients with ET, without overt atherosclerotic disease, carrying the mutation in the Janus kinase 2, (JAK2) V617F (present in a high number of subjects with myeloproliferative disorders) differed from control subjects in the progression of carotid artery stiffness and preclinical atherosclerosis. (eas-society.org)
- This implies that mutation precedes mitotic recombination which acts as a "second hit" responsible for removal of the remaining wild-type allele, as has recently been shown for the JAK2 gene in myeloproliferative disorders. (aacrjournals.org)
Chronic myeloproliferative diseases3
- Recently, chronic myeloproliferative diseases associated with pulmonary hypertension were included in the group 5 category, corresponding to PH for which the aetiology is unclear and/or multifactorial. (ersjournals.com)
- MPDs fall into 2 categories - acute myeloid leukemia and chronic myeloproliferative diseases. (wearethecure.org)
- Chronic myeloproliferative diseases are caused by an overabundance of differentiated bone marrow cells that result in the accumulation of erythrocytes, granulocytes, monocytes or platelets. (wearethecure.org)
Known as myeloproliferative2
- Ashley Gould, 23andMe's Vice President Corporate Development and Chief Legal Officer We recently topped our goal of enrolling 1,000 people with a group of rare blood disorders known as myeloproliferative. (23andme.com)
- ET is part of a group of conditions known as myeloproliferative disorders. (adam.com)
MPDs3
- Myeloproliferative disorders (MPDs) are a diverse group of conditions that are characterised by the overproduction of red cells, white cells and/or platelets in bone marrow . (radiopaedia.org)
- Description - Myeloproliferative diseases (MPDs) are a group of neoplastic ailments originating in the bone marrow. (wearethecure.org)
- These disorders were earlier referred to as acute MPDs or acute non-lymphocytic leukemias but now they have been brought under the ambit of acute myeloid leukemia. (wearethecure.org)
Diseases called myeloproliferative disorders1
- The new research demonstrates the importance of the hematopoietic microenvironment in the development of a group of potentially deadly diseases called myeloproliferative disorders. (eurekalert.org)
Leukemias and myeloproliferative disorders3
- The most common bone marrow disorders can be grouped into acute leukemias, chronic leukemias and myeloproliferative disorders. (aafp.org)
- He is committed to clinical and translational research aimed at developing new treatments for leukemias and myeloproliferative disorders. (petermac.org)
- This group of bone marrow disorders includes acute leukemias, chronic leukemias and myeloproliferative disorders. (ndtv.com)
Acute leukemias2
- We believe that this combined strategy will be more effective in preventing myeloproliferative disease progression and transformation in acute leukemias. (eurekalert.org)
- The editors have compiled an invaluable collection of cases covering common and rare entities-from anemias and acute leukemias to plasma cell, platelet and coagulation disorders. (ascp.org)
Hematologic2
- In rare cases, a hematologic disorder underlies sustained eosinophilia which can be either non-clonal or clonal. (haematologica.org)
- Dose escalation will proceed in cohorts comprised of two separate groups of patients (one group of patients with solid tumor/lymphoma and one group of patients with MDS), with at least 1 from each group, until hematologic DLT or the second grade 2. (aamds.org)
20165
- The research study offers an exclusive synopsis of the factors that are likely to have a lasting or short term impact on the growth of the Global myeloproliferative disorders clinical trials market professional survey report 2016 market during the forecast period. (qyresearchreports.com)
- The report accurately explores elements that are likely to have a stimulus or delayed effect on the Global myeloproliferative disorders clinical trials market professional survey report 2016 market in the short or long run. (qyresearchreports.com)
- The growth trajectory of the market has also been minutely studied with special attention on the drivers, restraints, and prospects present in the Global myeloproliferative disorders clinical trials market professional survey report 2016 market for the players and investors to look on to. (qyresearchreports.com)
- The report also provides an inclusive outlook of the elite companies operating in the Global myeloproliferative disorders clinical trials market professional survey report 2016 market. (qyresearchreports.com)
- With the help of this, the reader can have a clear picture of the competitive landscape of the players and a comprehension of the products and marketing tactics of the leading players in the Global myeloproliferative disorders clinical trials market professional survey report 2016 market. (qyresearchreports.com)
Leukemia18
- This phase I trial is studying the side effects and best dose of vorinostat when given together with cytarabine and etoposide in treating patients with relapsed or refractory acute leukemia or myelodysplastic syndromes or myeloproliferative disorders. (clinicaltrials.gov)
- I. Determine the feasibility, tolerability, and toxicities, in terms of the maximum tolerated dose (MTD), of the sequential combination of vorinostat (SAHA) followed by cytarabine and etoposide in patients with relapsed and/or refractory acute leukemia or transforming myelodysplastic syndromes or myeloproliferative disorders. (clinicaltrials.gov)
- Determine the incidence of subsequent leukemia in patients with transient myeloproliferative disorder treated with this regimen. (knowcancer.com)
- Determine the predictive risk factors for developing subsequent leukemia in patients with transient myeloproliferative disorder treated with this regimen. (knowcancer.com)
- 1 ] This category is composed of three major myeloid disorders: chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myeloid leukemia (aCML). (cigna.com)
- Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease? (cigna.com)
- Elevated Hemoglobin F levels are also associated with Leukemia and myeloproliferative disorders. (wikipedia.org)
- The lymphoid lineage may produce similar diseases, the lymphoproliferative disorders ( acute lymphoblastic leukemia , lymphomas , chronic lymphocytic leukemia and multiple myeloma ). (wikipedia.org)
- The team has shown that the microenvironment that controls hematopoietic stem cells can be targeted for the treatment of a set of disorders called myeloproliferative neoplasias, the most prominent of which are chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myelogenous leukemia (CML). (sciencecodex.com)
- Occasionally, leukocytosis is the sign of a primary bone marrow abnormality in white blood cell production, maturation or death (apoptosis) related to a leukemia or myeloproliferative disorder. (aafp.org)
- INDIANAPOLIS -- Like a line of falling dominos, a cascade of molecular events in the bone marrow produces high levels of inflammation that disrupt normal blood formation and lead to potentially deadly disorders including leukemia, an Indiana University-led research team has reported. (eurekalert.org)
- Dr Bajel is the member of scientific committees in the Australasian Leukemia and Lymphoma Group (ALLG) and CIBMTR. (petermac.org)
- MS usually presents in the setting of coexisting acute myeloid leukemia (AML) and myeloproliferative disorders. (hindawi.com)
- Many MS patients (if not most) have either a coexisting acute myeloid leukemia (AML), myeloproliferative, or myelodysplastic disorder at the time of diagnosis, or it appears at the first sign of relapse from one of these disorders. (hindawi.com)
- In one of the early descriptions of two cases (1), the authors concluded that this disorder was a variant of chronic myelogenous leukemia. (annals.org)
- The recent introduction of chromosomal analysis has been helpful in distinguishing chronic myelogenous leukemia within the group of myeloproliferative disorders, as have cytochemical techniques. (annals.org)
- Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative disorder of early childhood characterized by mutations activating RAS signaling. (uzh.ch)
- Chronic lymphocytic leukemia (CLL) is a generally slow-growing blood disorder. (msdmanuals.com)
Lymphoproliferative disorders1
- The association between residence close to high-voltage power lines and the risk of lymphoproliferative disorders or myeloproliferative disorders was investigated in a case-control study in Australia. (emf-portal.org)
Hematology2
- A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. (prolekare.cz)
- Participants from different parts of the world with knowledge on hematology are welcome to attend International Summit on Hematology and Blood disorders first time happening in Orlando, USA during October 29-31, 2020. (science-community.org)
Diagnosis8
- Diagnosis And Classification Of Myeloproliferative And. (bartleby.com)
- The clinical laboratory plays a prominent role in the diagnosis and classification of myeloproliferative and myelodysplastic disorders, each of which presents a unique set of morphologic, pathophysiologic, and genetic traits. (bartleby.com)
- Of these, 672 patients with the diagnosis of a Ph‑ negative chronic myeloproliferative disorder were evaluated. (prolekare.cz)
- Ho er medlem av Management Committee for COST Action BM 0902 Network of experts in the diagnosis of myeloproliferative disorders (MPD)/ MPN&MPNr-EuroNet. (tidsskriftet.no)
- MS is a rare extramedullary tumor, which should be considered in the differential diagnosis of a soft tissue mass involving the duodenum, especially if there is a coexisting hematological disorder. (hindawi.com)
- An overview of the myeloproliferative disorders, as well as discussions of pathogenetic mechanisms, clinical manifestations, and diagnosis of AMM are discussed separately. (bionity.com)
- Though myeloproliferative disorders are serious, and may pose certain health risks, people with these conditions often live for many years after diagnosis. (adam.com)
- Many people with myeloproliferative disorders have no symptoms when their doctors first make the diagnosis. (adam.com)
Splenomegaly3
- Background: The aim of our study was to measure the concentrations of: total serum cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), and triglycerides (TG), in patients splenectomised due to trauma as well as in those with splenomegaly caused by portal hypertension or myeloproliferative disorders. (medscimonit.com)
- In the case of splenomegaly mean values of: TC, and LDL-C, were significantly decreased than in the control group, no matter the reason of splenomegaly. (medscimonit.com)
- Material/Methods: Studies were carried out on 14 splenectomized patients, 17 with portal hypertension caused by liver cirrhosis and 8 with splenomegaly due to myeloproliferative disorders. (medscimonit.com)
Patients with myeloproliferative1
- In addition, elevated levels of the blocked molecule were found in samples from human patients with myeloproliferative disease. (eurekalert.org)
Heterogeneous3
- It is a heterogeneous disorder belonging to the group of myelodysplastic/myeloproliferative (MDS/MPN) syndromes. (wikipedia.org)
- Chronic myeloproliferative disorders (CMPDs) are a group of heterogeneous clonal stem cell disorders that can be defined by specific cytomorphological phenotypes and sometimes genetic features (1). (thefreelibrary.com)
- Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic condition in children and comprises of a heterogeneous group of seven different diseases, (1,2) Some JIA subtypes have increased susceptibility to develop inflammation of anterior or posterior chamber, known as uveitis. (thefreedictionary.com)
Hematopoietic stem1
- The findings, published today in Nature, demonstrate that these myeloproliferative neoplasias only appear after damage to the microenvironment that sustains and controls the hematopoietic stem cells-the cells that produce the cells of the blood and the immune system. (sciencecodex.com)
Overlap3
- The French-American-British classification scheme for myeloid disorders did not contain this overlap category, which made the classification of CMML particularly difficult. (cigna.com)
- 2 , 3 ] Recognizing the special diagnostic challenge that these diseases represent, a group of pathologists and clinicians sponsored by the World Health Organization (WHO) created the MDS/MPN category to provide a less restrictive view of myeloid disorders, which in some instances clearly overlap. (cigna.com)
- 2 MDS/MPN overlap disorders are those chronic myeloid disorders unable to be classified as "classic" MPN or MDS. (clevelandclinicmeded.com)
Overproduction4
- They are a group of four diseases characterised by an overproduction of one or more types of blood or fibre cells in the bone marrow. (labtestsonline.org.au)
- Myeloproliferative diseases in humans can result in several illnesses caused by overproduction of myeloid cells, which are normally are used to fight infections. (eurekalert.org)
- Myeloproliferative disorders are defined as a group of disorders characterized by the overproduction (proliferation) of the three main blood cell lines, red or white blood cells or platelets. (rarediseases.org)
- All myeloproliferative disorders are caused by overproduction of one or more types of cells. (adam.com)
Platelet count2
- Essential thrombocythemia is a clonal myeloproliferative disorder, characterized predominantly by a markedly elevated platelet count without known cause. (annals.org)
- Myelodysplastic syndromes are defined as a group of disorders that are characterized by disordered development of blood cells in the bone marrow that lead to cytopenias (low red cell and platelet count). (rarediseases.org)
Primary7
- Much less common but more serious causes include primary bone marrow disorders. (aafp.org)
- Primary bone marrow disorders should be suspected in patients who present with extremely elevated white blood cell counts or concurrent abnormalities in red blood cell or platelet counts. (aafp.org)
- The investigation of leukocytosis begins with an understanding of its two basic causes: (1) the appropriate response of normal bone marrow to external stimuli and (2) the effect of a primary bone marrow disorder. (aafp.org)
- We evaluated the rate of alloimmunization in two groups of chronically transfused patients (A - not phenotyped and B - phenotyped for Rh/K antigens before the first transfusion) with primary haematological disorders and its distribution among the main haematological diseases, in order to adopt an efficient transfusional strategy. (nih.gov)
- As methodology, we used the SIBAS and SAM databases for the retrospective study of all patients with primary haematological disorder between January 2011 and April 2013. (nih.gov)
- Much less common but more serious causes include primary bone marrow disorders and this is suspected in patients who present with extremely high white blood cell counts or concurrent abnormalities in red blood cell or platelet counts. (ndtv.com)
- The primary disease process in AMM is a clonal hematopoietic stem cell disorder which results in chronic myeloproliferation and atypical megakaryocytic hyperplasia. (bionity.com)
Proliferation1
- Chronic myeloproliferative disorders are also characterized by unregulated proliferation of cells that lead to the accumulation of differentiated cells. (wearethecure.org)
Thrombocythemia2
- Anagrelide is often used in the treatment of thrombocythemia in myeloproliferative disease (MPD), but information concerning effects of treatment on cytokines involved in regulation of blood platelet levels is limited. (medsci.org)
- Secondary thrombocythemia is excess platelets in the bloodstream that develops as a result of another disorder and rarely leads to excessive blood clotting or bleeding. (msdmanuals.com)
Essential1
- Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. (prolekare.cz)
Blood11
- Myeloproliferative and myelodysplastic syndromes, two diverse groups of bone marrow disorders, are respectively characterized by an overproliferation or ineffective production of various blood cells. (bartleby.com)
- Another blood cell disorder. (mayoclinic.org)
- TLS is a group of problems with blood levels, including high levels of uric acid (hyperuricemia), potassium (hyperkalemia) and phosphate (hyperphosphatemia), and low levels of calcium (hypocalcemia). (cancer.ca)
- TLS is more likely to develop when certain cancers or blood disorders are treated with chemotherapy. (cancer.ca)
- The discovery, published by the journal Cell Stem Cell , points the way to potential new strategies to treat the blood disorders and further illuminates the relationship between inflammation and cancer, said lead investigator Nadia Carlesso, M.D., Ph.D., associate professor of pediatrics at the Indiana University School of Medicine. (eurekalert.org)
- In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. (cancerconnect.com)
- The disorder is characterized by the uncontrolled growth of an immature form of a specific type of white blood cell known as monocytes. (rarediseases.org)
- Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. (northwestern.edu)
- It is these clonal disorders in the bone marrow that actually lead to myeloaplasia (low count of all blood cell lines like red blood cells, white blood cells and platelets), myelodysplasia (group of disorders in which the bone marrow does not function properly and produces insufficient number of blood cells) and myeloproliferation. (wearethecure.org)
- Both programs aim to engineer human cells into new generations of cells and tissues for patients suffering from blood diseases, cancer and, likely, a greater range of other disorders. (chop.edu)
- The researchers also monitored the number of phlebotomy procedures (procedure to draw blood that is used to manage PV) needed to treat PV in both groups. (unm.edu)
Lymphomas1
Bone Marrow1
- Here we report a 66-year-old male patient whose bone marrow biopsy revealed signs of chronic myeloproliferative changes and dysmegakaryopoiesis. (thefreelibrary.com)
Coagulation Disorders2
- Coagulation Disorders (incl. (healthgrades.com)
- There was no family history for coagulation disorders. (termedia.pl)
Clonal stem cell1
- Myelodysplastic syndromes (MDSs) are a collection of clonal stem cell hematopoietic disorders that are characterized by ineffective hematopoiesis, multilineage dysplasia, peripheral cytopenias, and susceptibility to leukemic transformation. (springer.com)
Molecular1
- In 2005, the discovery of the JAK2V617F mutation provided the first evidence that a fraction of persons with these disorders have a common molecular pathogenesis. (wikipedia.org)
Jakafi3
- They were divided into two study groups: one received Jakafi, and the other received standard therapy (which is often Hydrea). (unm.edu)
- Furthermore, more patients on Jakafi experienced remission: 24% versus 9% of those in the standard-therapy group. (unm.edu)
- They were divided into two treatment groups: 110 received Jakafi and 112 received best available therapy. (unm.edu)
Platelets1
Pulmonary Hypertension2
- Pulmonary hypertension (PH) is a severe haemodynamic disorder in which the pulmonary artery pressure is persistently elevated, leading to right-sided heart failure and death. (ersjournals.com)
- In this review we will describe the distinct forms of PH in the context of the myeloproliferative diseases chronic thromboembolic pulmonary hypertension and pre-capillary PH mimicking pulmonary arterial hypertension. (ersjournals.com)
Treatment1
- It is critical to go through the appropriate diagnostic tests to determine whether your patient has PAH versus PH related to other underlying systemic disorders since treatment approaches are vastly different. (renalandurologynews.com)